Drug firm Mylan Pharmaceuticals today said it has launched tenofovir alafenamide tablets under the brand name ‘HepBest’, used for treatment of chronic hepatitis B in adults, in India.
HepBestTM is the first drug in eight years to be approved for the management of chronic hepatitis B in India, Mylan Pharmaceuticals Pvt Ltd said in a statement.
The tablet has been launched in the strength of 25 mg, it added.
Commenting on the development, Mylan India and Emerging Markets President Rakesh Bamzai said: “Mylan continues to be in the forefront of introducing new treatment regimens for the management of hepatitis in India.”
By bringing the best-in-class drug for hepatitis B management, HepBestTM, to India, Mylan hopes to provide care for chronic hepatitis B patients and improve overall management of the disease, he added.
Comments
Comments have to be in English, and in full sentences. They cannot be abusive or personal. Please abide by our community guidelines for posting your comments.
We have migrated to a new commenting platform. If you are already a registered user of TheHindu Businessline and logged in, you may continue to engage with our articles. If you do not have an account please register and login to post comments. Users can access their older comments by logging into their accounts on Vuukle.